Bristol-Myers Squibb is one of the most productive pharmaceutical companies in the United States, as well as on the global scale. With a strong focus on the wellness of patients, this company has grown into a pharmaceutical research and development machine, with a mission to make the world a healthier place.

A Quick History

The Bristol-Myers Squibb Company is composed of two main components: Bristol-Myers and Squibb. Bristol-Myers began as the Clinton Pharmaceutical Company in 1887 in Clinton, New York. The partners William McLaren Bristol and John Ripley Myers changed the name in 1898 to Bristol-Myers Company. Squibb, however, was created by Edward Robinson Squibb in Brooklyn, New York in 1858. Then, in 1895 the company became Squibb and Sons. Each company grew and saw many medical achievements. In 1989 the two companies merged, creating Bristol-Myers Squibb.

Products Offered by the Bristol-Myers Squibb Company

As one of the major pharmaceutical companies in the industry, Bristol-Myers Squibb offers several different types of products for consumers. These include prescription drugs, over the counter medicines and medicines created to specifically target infectious diseases, as well as types of cancers. Examples of over-the-counter products include Enfamil, a well known infant formula, and Excedrin headache and migraine pain relievers. In the treatment of cancer, Bristol-Myers Squibb has created Erbitux. For the treatment of infectious diseases, such as hepatitis B, the company has created Baraclude, Reyataz, Sustiva, Tequin, Videx and Zerit. Still, the Bristol-Myers Squibb Company also creates products for cardiovascular diseases, mental disorders, disorders of the nervous system, wound therapies and many more.

The Future of Bristol-Myers Squibb: The R&D Department

R&D in the pharmaceutical world stands for research and development, a key component of most large pharmaceutical companies. Bristol-Myers Squibb is no different in this respect. Bristol-Myers Squibb company has seven major research facilities, including Princeton, Hopewell and New Brunswick, New Jersey; Wallingford, Connecticut; Braine L’alleud, Belgium; Moreton, England and one in Singapore. Recent numbers suggest that approximately $2.3 billion dollars have been spent toward the future of drug research and development at Bristol-Myers Squibb. The company’s employees number close to 5,000 individuals. The company is currently working on medicines to treat illnesses such as Alzheimer’s, cancer, diabetes, HIV and obesity.

contact@bigpharmadeals.com